Valuation : Exact Sciences Corporation

Market Cap 20.03B 17.23B 16.23B 14.78B 27.66B 1,906B 27.77B 192B 74.32B 971B 75.2B 73.56B 3,076B P/E 2024
-10.1x
P/E 2025 -92.2x
Enterprise Value 21.6B 18.58B 17.5B 15.94B 29.83B 2,055B 29.95B 207B 80.15B 1,047B 81.09B 79.33B 3,317B EV / Sales 2024
4.4x
EV / Sales 2025 6.42x
Free-Float
98.24%
Yield 2024 *
-
Yield 2025 -
1 day+0.95%
6 months+1.16%
Current year+3.30%
Current year 101.51
Extreme 101.51
104.98
1 year 51.75
Extreme 51.75
104.98
3 years 38.81
Extreme 38.8118
104.98
5 years 29.27
Extreme 29.27
108.99
10 years 13.05
Extreme 13.05
159.54
Date Insider Type Main position Quantity % Market Cap. Importance
3/23/26 Issuer sale

Director

28,899 0.0151%
3/23/26 Free

Executive/Senior Manager

199,374 0.1044%
3/23/26 Issuer sale

Director

20,558 0.0108%
Change 5-day change 1-year change 3-year change Capi.($)
+0.95%-.--%+89.33%+33.93% 20.03B
-3.10%-2.20%+255.70%+41.68% 3.94B
+0.33%-0.97%+93.66%+307.00% 3.88B
+3.32%-2.27%+37.11%+77.71% 3.41B
-0.56%+0.87%+271.97%+512.36% 2.6B
-1.26%-4.86%-30.72%-29.85% 2.13B
-3.49%+2.26%+54.60% - 1.72B
-3.34%-5.83%+161.28%-35.83% 1.07B
-3.50%-8.03%+17.64%+36.40% 1.07B
+1.04%-5.08%+6.81%+55.52% 617M
Average -0.96%+0.92%+95.74%+110.99% 4.05B
Weighted average by Cap. +0.06%+0.69%+104.24%+93.05%

Financials

2024 2025
Net sales 2.76B 2.37B 2.24B 2.04B 3.81B 263B 3.83B 26.49B 10.24B 134B 10.36B 10.13B 424B 3.25B 2.79B 2.63B 2.4B 4.49B 309B 4.5B 31.18B 12.05B 157B 12.19B 11.93B 499B
Net income -1.03B -885M -834M -760M -1.42B -97.9B -1.43B -9.88B -3.82B -49.88B -3.86B -3.78B -158B -208M -179M -168M -154M -287M -19.79B -288M -2B -772M -10.08B -781M -764M -31.94B
Net Debt 1.74B 1.5B 1.41B 1.28B 2.4B 165B 2.41B 16.69B 6.45B 84.24B 6.53B 6.38B 267B 1.57B 1.35B 1.27B 1.16B 2.17B 149B 2.18B 15.08B 5.83B 76.11B 5.9B 5.77B 241B
Logo Exact Sciences Corporation
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. It offers a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. Its portfolio includes brands such as Cologuard and Oncotype DX, along with solutions like Cancerguard for blood-based analysis of molecular information across multiple cancers and Oncodetect for molecular residual disease and recurrence monitoring. Its flagship screening products, the Cologuard and Cologuard Plus tests, are patient-friendly, non-invasive, stool-based DNA (sDNA) screening tests that utilize a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Its Cancerguard test is designed to detect multiple cancers in their earliest stages from a single blood draw. It offers predefined genetic tests for all clinically relevant genes, and whole genome (PGnome) sequencing tests.
Employees
7,150
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
AAA
  1. Stock Market
  2. Stocks
  3. EXAS Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!